These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 21393075)

  • 1. Biological challenges of BRAF inhibitor therapy.
    Puzanov I; Burnett P; Flaherty KT
    Mol Oncol; 2011 Apr; 5(2):116-23. PubMed ID: 21393075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting BRAF in melanoma: biological and clinical challenges.
    Mandalà M; Voit C
    Crit Rev Oncol Hematol; 2013 Sep; 87(3):239-55. PubMed ID: 23415641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic
    Delord JP; Robert C; Nyakas M; McArthur GA; Kudchakar R; Mahipal A; Yamada Y; Sullivan R; Arance A; Kefford RF; Carlino MS; Hidalgo M; Gomez-Roca C; Michel D; Seroutou A; Aslanis V; Caponigro G; Stuart DD; Moutouh-de Parseval L; Demuth T; Dummer R
    Clin Cancer Res; 2017 Sep; 23(18):5339-5348. PubMed ID: 28611198
    [No Abstract]   [Full Text] [Related]  

  • 4. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].
    Capovilla M
    Ann Pathol; 2013 Dec; 33(6):375-85. PubMed ID: 24331719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
    Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
    Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF inhibitors and melanoma.
    Flaherty KT
    Cancer J; 2011; 17(6):505-11. PubMed ID: 22157295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status.
    Izar B; Sharfman W; Hodi FS; Lawrence D; Flaherty KT; Amaravadi R; Kim KB; Puzanov I; Sosman J; Dummer R; Goldinger SM; Lam L; Kakar S; Tang Z; Krieter O; McDermott DF; Atkins MB
    Cancer Med; 2017 Aug; 6(8):1904-1914. PubMed ID: 28719152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Implications of Acquired BRAF Inhibitors Resistance in Melanoma.
    Savoia P; Zavattaro E; Cremona O
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33419275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BRAF, a target in melanoma: implications for solid tumor drug development.
    Flaherty KT; McArthur G
    Cancer; 2010 Nov; 116(21):4902-13. PubMed ID: 20629085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Developments in the Space of New MAPK Pathway Inhibitors for BRAF-Mutant Melanoma.
    Cohen JV; Sullivan RJ
    Clin Cancer Res; 2019 Oct; 25(19):5735-5742. PubMed ID: 30992297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma.
    Richman J; Martin-Liberal J; Diem S; Larkin J
    Expert Opin Pharmacother; 2015 Jun; 16(9):1285-97. PubMed ID: 26001180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [BRAF inhibitor and MEK inhibitor].
    Uhara H
    Gan To Kagaku Ryoho; 2015 Apr; 42(4):428-33. PubMed ID: 26020982
    [No Abstract]   [Full Text] [Related]  

  • 13. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.
    Grimaldi AM; Simeone E; Festino L; Vanella V; Palla M; Ascierto PA
    Discov Med; 2015 Jun; 19(107):455-61. PubMed ID: 26175403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF
    Hong SP; Ahn SK
    Life Sci; 2017 Aug; 183():37-44. PubMed ID: 28645859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapy for the adjuvant treatment of stage III BRAF-mutated melanoma.
    Long G
    Clin Adv Hematol Oncol; 2018 Jan; 16(1):25-27. PubMed ID: 29741501
    [No Abstract]   [Full Text] [Related]  

  • 16. MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition.
    Amaral T; Sinnberg T; Meier F; Krepler C; Levesque M; Niessner H; Garbe C
    Eur J Cancer; 2017 Mar; 73():93-101. PubMed ID: 28162869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor.
    Bonnevaux H; Lemaitre O; Vincent L; Levit MN; Windenberger F; Halley F; Delorme C; Lengauer C; Garcia-Echeverria C; Virone-Oddos A
    Mol Cancer Ther; 2016 Jul; 15(7):1460-71. PubMed ID: 27196754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF in melanoma: current strategies and future directions.
    Salama AK; Flaherty KT
    Clin Cancer Res; 2013 Aug; 19(16):4326-34. PubMed ID: 23770823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
    Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
    Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma.
    Carlino MS; Long GV; Kefford RF; Rizos H
    Crit Rev Oncol Hematol; 2015 Dec; 96(3):385-98. PubMed ID: 26358420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.